[Cerebroprotection with calcium channel blockers].
Mogi
Masaki
M
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine.
Iwai
Masaru
M
Horiuchi
Masatsugu
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D002544:Cerebral Infarction / Q000209:etiology / Q000517:prevention & control*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress
D047228:Angiotensin II Type 1 Receptor Blockers; D000975:Antioxidants; D002121:Calcium Channel Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009569:Nitric Oxide